Hydrix Group’s innovation engine delivers world class design, engineering and regulatory services
Diagnostic, monitoring & interventional MedTech products which improve patient quality of life
Pick winning investments in high potential client medical technologies
14 SEPTEMBER 2021 ASX Announcement - Hydrix On Track for Cardiac Product Sales in H1 CY22
31 AUGUST 2021 Letter from Executive Chairman
31 AUGUST 2021 Appendix 4E and Financial Report
31 AUGUST 2021 Proposed issue of securities
31 AUGUST 2021 Commercial arrangement between Hydrix and Memphasys
2 AUGUST 2021 ASX Announcement - US Implant AngelMed Guardian
29 JULY 2021 Quarterly Activities Report and Appendix 4C
30 JUNE 2021 ASX Announcement - Investor Presentation re. AngelMed Guardian FDA Approval
28 JUNE 2021 ASX Announcement - FDA approval AngelMed Guardian
29 April 2021 Quarterly Activities Report and Appendix 4C
To view past announcements visit the Hydrix page on the ASX
Please click the image above to access our Annual Report
Please click the image above to access our Shareholder Newsletter
For all shareholder enquiries, please contact us via the form below:
To view the latest Hydrix share price and announcements, visit the Hydrix page on the ASX
Hydrix Executive Chairman, Gavin Coote, presents to the Bell Potter Network
Hydrix Executive Chairman, Gavin Coote speaks to Proactive's Andrew Scott regarding the AngelMed FDA approval
Hydrix Executive Chairman, Gavin Coote, hosted an investor conference call to discuss financial results
The Market Unpacked interviews Gavin Coote, Hydrix Executive Chairman
Journalist Tim Boreham discovers a quiet achiever propelling the MedTech industry
